ATE314116T1 - Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren - Google Patents

Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren

Info

Publication number
ATE314116T1
ATE314116T1 AT96929058T AT96929058T ATE314116T1 AT E314116 T1 ATE314116 T1 AT E314116T1 AT 96929058 T AT96929058 T AT 96929058T AT 96929058 T AT96929058 T AT 96929058T AT E314116 T1 ATE314116 T1 AT E314116T1
Authority
AT
Austria
Prior art keywords
protease inhibitors
roxithromycin
medication
biological
producing
Prior art date
Application number
AT96929058T
Other languages
English (en)
Inventor
Raymond F Schinazi
Jean-Pierre Sommadossi
Original Assignee
Uab Research Foundation
Raymond F Schinazi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, Raymond F Schinazi filed Critical Uab Research Foundation
Application granted granted Critical
Publication of ATE314116T1 publication Critical patent/ATE314116T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • C07H15/16—Lincomycin; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96929058T 1995-08-30 1996-08-30 Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren ATE314116T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/521,474 US5750493A (en) 1995-08-30 1995-08-30 Method to improve the biological and antiviral activity of protease inhibitors
PCT/US1996/013721 WO1997008180A1 (en) 1995-08-30 1996-08-30 Method to improve the biological and antiviral activity of protease inhibitors

Publications (1)

Publication Number Publication Date
ATE314116T1 true ATE314116T1 (de) 2006-01-15

Family

ID=24076871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96929058T ATE314116T1 (de) 1995-08-30 1996-08-30 Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren

Country Status (11)

Country Link
US (1) US5750493A (de)
EP (1) EP0876387B1 (de)
JP (1) JP4335311B2 (de)
KR (1) KR100454663B1 (de)
AT (1) ATE314116T1 (de)
AU (1) AU716821B2 (de)
DE (1) DE69635671T2 (de)
DK (1) DK0876387T3 (de)
ES (1) ES2257752T3 (de)
PT (1) PT876387E (de)
WO (1) WO1997008180A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US20020068749A1 (en) * 1996-11-08 2002-06-06 Hideharu Sato Aids remedy
US6180634B1 (en) * 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US7087373B2 (en) 2001-06-05 2006-08-08 Tibotec Pharmaceuticals Ltd. Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteins
EP1482957A4 (de) * 2002-02-15 2006-07-19 Merckle Gmbh Antibiotische konjugate
NZ535354A (en) 2002-02-15 2008-01-31 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1483579A4 (de) * 2002-02-15 2006-07-12 Merckle Gmbh Konjugate biologisch aktiver verbindungen, verfahren zu ihrer herstellung und verwendung, formulierung und pharmazeutische anwendungen davon
AU2003208751A1 (en) * 2002-02-22 2003-09-09 Tibotec Bvba Methods for determining the influence of protein binding on antiretroviral activity
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
WO2003090691A2 (en) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
BR0315795A (pt) * 2002-10-31 2005-09-13 Metabasis Therapeutics Inc Pró-medicamentos de monofosfato de citarabina
AU2004273773B2 (en) * 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
JP2006524710A (ja) * 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7273717B2 (en) * 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
JP2007515495A (ja) * 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
WO2007012464A1 (en) * 2005-07-26 2007-02-01 Merckle Gmbh Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase
MX2008007790A (es) * 2005-12-22 2009-03-04 Anaborex Inc Composiciones y metodos para la prevencion y tratamiento de caquexia.
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
DE602008005896D1 (de) * 2007-06-22 2011-05-12 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
SI2170292T1 (sl) * 2007-06-22 2014-05-30 Bristol-Myers Squibb Holdings Ireland Tabletirani sestavki, ki vsebujejo atazanavir
US20100178340A1 (en) * 2007-06-22 2010-07-15 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
FR3049861A1 (fr) * 2016-04-07 2017-10-13 Univ Claude Bernard Lyon Nouvelles compositions antivirales pour le traitement de la grippe
EP3661937B1 (de) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Kristalline formen von ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) zur behandlung von viralen infektionen
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
US5461067A (en) * 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics

Also Published As

Publication number Publication date
US5750493A (en) 1998-05-12
AU6860196A (en) 1997-03-19
WO1997008180A1 (en) 1997-03-06
PT876387E (pt) 2006-05-31
EP0876387A1 (de) 1998-11-11
KR100454663B1 (ko) 2004-12-29
DK0876387T3 (da) 2006-05-29
JP4335311B2 (ja) 2009-09-30
DE69635671D1 (de) 2006-02-02
KR19990044262A (ko) 1999-06-25
AU716821B2 (en) 2000-03-09
DE69635671T2 (de) 2006-09-07
ES2257752T3 (es) 2006-08-01
EP0876387B1 (de) 2005-12-28
JP2001500471A (ja) 2001-01-16
EP0876387A4 (de) 1999-12-01

Similar Documents

Publication Publication Date Title
ATE314116T1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
WO2003034803A3 (en) Methods for determining toxicity reversing agents
ATE276764T1 (de) Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69910045D1 (de) Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
ATE179429T1 (de) Cytokine dämpfende substanzen
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
ATE306473T1 (de) Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
YU66000A (sh) Antipikovirusna jedinjenja, njihovo dobijanje i upotreba
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
BR0304963A (pt) Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
AU2001232736A1 (en) Protein c derivatives
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
WO2003065978A3 (en) Crystals and structures of a flavin mononucleotide binding protein (fmnbp)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0876387

Country of ref document: EP

REN Ceased due to non-payment of the annual fee